The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.
The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.
Transcript
What was the toxicity seen in the phase 2 ZUMA-3 trial of brexucabtagene autoleucel?
I think the good news is most of the toxicity was consistent with what we saw in the phase 1 trial. You know, we saw anemia, we saw thrombocytopenia, we saw, you know, fevers and the like. I think that we did unexpectedly see 1 case of cerebral edema, which was fatal for one of our patients. And, you know, I said this a few times now, with different interviews: It's still really hard for me to wrap my head around. On the one hand, you we have to acknowledge this is a CAR [chimeric antigen receptor] T-cell–associated toxicity. On the other hand, we have to acknowledge it is extraordinarily uncommon.
And the other thing that's really interesting about the brain swelling is, although we classify it as a neurologic toxicity, because it impacts the brain, why is it occurring during what we call the CRS [cytokine release syndrome] phase, meaning that period where we see fever and hypotension or can see hypotension if that occurs? Why is it occurring during that initial sort of phase as T cells are really expanding and doing their job of killing leukemia? So, it's rare, and it's occurring when it's not supposed to, meaning it's been earlier than most cases. And I will just be blunt: I don't think we understand the biology of it, period. And I think that that's something that we all want to be able to understand and hopefully prevent, as we move forward.
One of the things that I was really excited about on this particular trial was the early initiation of tocilizumab and steroids. And, you know, really, we intervened for very low-grade toxicity to try and prevent these kinds of events. I would say that that also underscores the success that we saw as it relates to safety. If you look, overall, we had around 25% grade 3 and above CRS rate, 25% roughly grade 3 and above neurotoxicity rate. And for an adult population with high-burden ALL [acute lymphocytic leukemia], that's also unparalleled, and that's really, really, really good. You know, those rates are not that dissimilar from what we saw in large cell lymphoma, in mantle cell lymphoma, and the like. And so I'm really quite proud of achieving those benchmarks. But again, it's because of the early intervention that we were able to mitigate much of the toxicity.
Interestingly, it didn't seem to come with any impact on response. And so, you know, I tell people, often I said, steroids are fine, just you have to control it. You know, steroids for 2 weeks is probably not fine, but a short exposure to steroids, if you believe the patient needs it, it is probably going to be okay. You're not really going to impair the efficacy of the CAR T-cell immunotherapy. Same thing goes for tocilizumab, where we can’t say there's any impact. And so with very simple measures, controlling the toxicity, we can really improve the course for a lot of our patients.
And if you read between the lines, where we talk about both—where we saw our best responses, but also where we saw toxicity—and if you understand that we were intervening early for that toxicity, you'll see that in spite of early intervention and those who had grade 2 and above CRS, in spite of early intervention for neurotoxicity, you could still see phenomenal expansion, and you can see that that also translated into a higher likelihood of complete remissions.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More